Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07090499
PHASE1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Sponsor: Pfizer

View on ClinicalTrials.gov

Summary

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Official title: A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

310

Start Date

2025-08-20

Completion Date

2029-07-08

Last Updated

2026-04-07

Healthy Volunteers

No

Interventions

DRUG

PF-08046876

Intravenous administration

Locations (28)

City of Hope National Medical Center

Duarte, California, United States

City of Hope at Irvine Lennar

Irvine, California, United States

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

UCLA Department of Medicine-Hematology/Oncology

Los Angeles, California, United States

Santa Monica UCLA Medical Center & Orthopaedic Hospital

Santa Monica, California, United States

UCLA Hematology/Oncology - Santa Monica

Santa Monica, California, United States

Smilow Cancer Hospital - Yale New Haven Health

New Haven, Connecticut, United States

Yale - New Haven Hospital - Yale Cancer Center

New Haven, Connecticut, United States

Smilow Cancer Hospital Phase 1 Unit

New Haven, Connecticut, United States

Smilow Cancer Hospital - Trumbull

Trumbull, Connecticut, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Dana-Farber Cancer Institute - Chestnut Hill

Newton, Massachusetts, United States

Sarah Cannon Research Institute - Pharmacy

Nashville, Tennessee, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center - Conroe

Conroe, Texas, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

The University of Texas, MD Anderson Cancer Center - West Houston

Houston, Texas, United States

The University of Texas, MD Anderson Cancer Center - League City

League City, Texas, United States

NEXT Oncology

San Antonio, Texas, United States

The University of Texas, MD Anderson Cancer Center - Sugar Land

Sugar Land, Texas, United States

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Pan American Center for Oncology Trials, LLC

Rio Piedras, Puerto Rico

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [barcelona], Spain

Hospital Universitario 12 de Octubre

Madrid, Madrid, Comunidad de, Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain

Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom